<DOC>
	<DOCNO>NCT00124865</DOCNO>
	<brief_summary>This study open-labeled dose escalate trial total 32 subject receive one four intranasal rFla-MBP vaccine dos .</brief_summary>
	<brief_title>Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine ( rFla-MBP ) Dose-Ranging Study</brief_title>
	<detailed_description>This open label dose escalate trial total 32 subject receive one four intranasal rFla-MBP vaccine dos accord follow chart : Group / N* / rFla-MBP A / 8/ 25 microgram B / 8/ 125 microgram C / 8/ 625 microgram D / 8/ 1000 microgram * minimum 6 volunteer per group An interval less 60 day follow first dose separate first dose volunteer group receive different rFla-MBP dos . All volunteer receive three immunization . The first dosing time point Day 0 , second Day 14 ( +/- 1 day ) , third day 28 ( +/- 2 day ) . Blood stool specimen collect interval examine systemic mucosal vaccine antigen-specific immune response . Vaccine safety actively monitor vaccination 28 day follow third vaccine dose .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Healthy adult 70 % accuracy comprehension test Availability require visit telephone follow Pregnancy breastfeed Chronic health problem Abnormalities find physical examination Use immunosuppressive drug , corticosteroid chemotherapy Positive blood test HIV1 , hepatits B surface antigen ( HBsAG ) hepatitis C virus ( HCV ) Abnormalities find basic laboratory screen Prior exposure Campylobacter Current smoker Chronic sinusitis seasonal rhinitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Campylobacter</keyword>
	<keyword>Bacterial enteritis</keyword>
</DOC>